Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro.
Liu Z-J. et al, (2022), Blood Adv, 6, 13 - 27
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
Mead AJ. et al, (2022), Ther Adv Hematol, 13
A Review of the Prevention of Mother-to-Child Transmission of Human T-Cell Lymphotrophic Virus Type 1 (HTLV-1) With a Proposed Management Algorithm.
Barr RS. et al, (2022), Front Med (Lausanne), 9
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA).
Infante MS. et al, (2022), Front Oncol, 12
Defining disease modification in myelofibrosis in the era of targeted therapy
Pemmaraju N. et al, (2022), Cancer
Mutation agnostic diagnosis of clonal hematopoiesis of indeterminate potential (CHIP) using fluctuating methylation clocks
Schenck RO. et al, (2022), CANCER RESEARCH, 82
Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic.
Skolariki A. et al, (2022), Explor Target Antitumor Ther, 3, 172 - 199
Ezh2 is essential for the generation of functional yolk sac derived erythro-myeloid progenitors.
Neo WH. et al, (2021), Nat Commun, 12
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial.
Schwenzer H. et al, (2021), Clin Cancer Res, 27, 6500 - 6513
A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program.
Rice S. et al, (2021), Nat Commun, 12
A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis
Gill H. et al, (2021), BLOOD, 138
Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of TP53 Mutated Leukemic Transformation in MPN
Rodriguez-Meira A. et al, (2021), BLOOD, 138
Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT.
Nwolise C. et al, (2021), Chronic Illn
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Collins GP. et al, (2021), Leuk Lymphoma, 62, 2625 - 2636
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.
Collins GP. et al, (2021), Hemasphere, 5
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Weber JS. et al, (2021), Eur J Cancer, 158, 225 - 233
The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders.
Cross NCP. et al, (2021), Br J Haematol, 195, 338 - 351
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M. et al, (2021), J Hematol Oncol, 14
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer
Kazmi F. et al, (2021), Cochrane Database of Systematic Reviews, 2021
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.
Fox CP. et al, (2021), Blood Adv, 5, 4073 - 4082